Long-term oral treatment of urinary tract infections with single daily doses of a new antibacterial drug combination (Kelfiprim).
Of 30 patients with severe, complicated U.T.I. 27 have been given single daily doses of Kelfiprim (KP), a new sulfatrimethoprim combination, for 8 weeks. In 24 bacteriuria was lastingly controlled, one had a relapse, one had a reinfection, and in one, with bladder carcinoma, bacteriuria persisted. Three other patients received KP for shorter periods, as they presented gastric intolerance or skin hypersensitivity, but in two of them a lasting sterilization of the urine has been obtained. The usefulness of a single daily dose schedule is stressed.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D003556:Cystitis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000008:administration & dosage; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy; D012008:Recurrence; D013415:Sulfalene / Q000008:administration & dosage*; D013424:Sulfanilamides / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D013424:Sulfanilamides; C026911:kelfiprim; D014295:Trimethoprim; D013415:Sulfalene